{"id":61588,"date":"2024-03-03T05:46:41","date_gmt":"2024-03-03T05:46:41","guid":{"rendered":"https:\/\/medsname.com\/atorvatin\/"},"modified":"2026-05-01T10:49:17","modified_gmt":"2026-05-01T10:49:17","slug":"atorvatin","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/atorvatin\/","title":{"rendered":"Atorvatin"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Atorvatin?<\/h3>\n<p style=\"margin:0;\"><strong>Atorvatin<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 <strong>5 mg atorvastatin tablet<\/strong> from a WHO-GMP certified manufacturer &mdash; a high-intensity HMG-CoA reductase inhibitor (statin), lipophilic. Statins reduce cardiovascular events by <strong>20-30% per mmol\/L LDL-cholesterol reduction<\/strong> across primary prevention, secondary prevention, diabetes, and post-stroke populations. Atorvastatin was introduced by Parke-Davis\/Pfizer in 1996 as <strong>Lipitor<\/strong> &mdash; the best-selling drug of all time at its peak ($12.5 billion\/year in 2006). Lipophilic statin, hepatically cleared via CYP3A4. Dose range 10-80 mg once daily; 40-80 mg are high-intensity by AHA\/ACC 2018 lipid guidelines. Potency: atorvastatin 40 mg typically reduces LDL-C by 50%; 80 mg by 55%. Typical dose: once daily, evening (for short-half-life statins) or any time for atorvastatin (half-life long enough that timing does not matter). Main side effects: muscle symptoms (0.1-1% with confirmed CK elevation; up to 10% nocebo muscle aches), mild transaminase elevation (3%), new-onset diabetes in at-risk patients (~0.2 per 100 patient-years). Absolutely contraindicated in pregnancy, active liver disease, rhabdomyolysis history.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 <a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\"><strong>\u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n<h2 class=\"wp-block-heading\">What Is Atorvatin?<\/h2>\n<p>Atorvatin is an oral 5 mg atorvastatin tablet from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Atorvastatin was introduced by Parke-Davis\/Pfizer in 1996 as <strong>Lipitor<\/strong> &mdash; the best-selling drug of all time at its peak ($12.5 billion\/year in 2006). Lipophilic statin, hepatically cleared via CYP3A4. Dose range 10-80 mg once daily; 40-80 mg are high-intensity by AHA\/ACC 2018 lipid guidelines.<\/p>\n<h2 class=\"wp-block-heading\">How Atorvastatin Works<\/h2>\n<p>Atorvastatin inhibits <strong>HMG-CoA \u03b1\u03bd\u03b1\u03b3\u03c9\u03b3\u03ac\u03c3\u03b7\u03c2<\/strong>, the rate-limiting enzyme of hepatic cholesterol biosynthesis. Downstream:<\/p>\n<ul>\n<li><strong>Reduced intracellular cholesterol in hepatocytes<\/strong> &mdash; triggers sterol-regulatory element binding protein (SREBP) activation and upregulation of LDL-receptor expression on the hepatocyte surface<\/li>\n<li><strong>Increased clearance of circulating LDL-C<\/strong> &mdash; the primary LDL-lowering mechanism<\/li>\n<li><strong>Modest triglyceride reduction<\/strong> (10-20%) and modest HDL rise (5-10%)<\/li>\n<li><strong>Pleiotropic effects<\/strong> beyond LDL-lowering &mdash; reduced vascular inflammation (hs-CRP drop), improved endothelial function, plaque stabilisation, reduced platelet reactivity. The magnitude of the clinical benefit across trials exceeds what is explained by LDL-C change alone.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Atorvatin Dosage<\/h2>\n<p><strong>Primary prevention (no prior CV event):<\/strong> start 10-20 mg once daily; titrate to target based on 10-year ASCVD risk. For diabetics or ASCVD risk &gt;7.5%, moderate-intensity (20-40 mg) is typical.<\/p>\n<p><strong>Secondary prevention (prior MI, stroke, PAD, or diabetic CVD):<\/strong> high-intensity therapy &mdash; 40-80 mg once daily. Target LDL-C &lt;1.8 mmol\/L (&lt;70 mg\/dL) per 2019 ESC and &lt;1.4 mmol\/L (&lt;55 mg\/dL) for very-high-risk ASCVD per 2021 ESC update.<\/p>\n<p><strong>Familial hypercholesterolaemia:<\/strong> maximum-tolerated statin (usually 80 mg) often combined with ezetimibe 10 mg and\/or PCSK9 inhibitor (alirocumab\/evolocumab\/inclisiran) to achieve guideline targets.<\/p>\n<p><strong>\u03a7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7:<\/strong> once daily with or without food. Evening dosing is no longer required for atorvastatin (long half-life); any consistent time of day is fine.<\/p>\n<p><strong>\u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7:<\/strong><\/p>\n<ul>\n<li><strong>\u0392\u03b1\u03c3\u03b9\u03ba\u03ae \u03b1\u03be\u03b9\u03bf\u03bb\u03cc\u03b3\u03b7\u03c3\u03b7:<\/strong> full lipid panel, LFTs (ALT), creatine kinase (CK), HbA1c or fasting glucose, creatinine, thyroid-stimulating hormone (TSH) if not recently checked.<\/li>\n<li><strong>4-12 weeks:<\/strong> repeat lipids to assess response. Expect atorvastatin 40 mg typically reduces LDL-C by 50%; 80 mg by 55%. Dose-escalate if target not met.<\/li>\n<li><strong>\u0395\u03c4\u03ae\u03c3\u03b9\u03b1:<\/strong> lipids, LFTs (unless symptomatic). CK only on muscle complaints, not routinely.<\/li>\n<li><strong>\u0394\u03b9\u03b1\u03ba\u03bf\u03c0\u03ae \u03ba\u03b1\u03b9 \u03b4\u03b9\u03b5\u03c1\u03b5\u03cd\u03bd\u03b7\u03c3\u03b7:<\/strong> CK &gt;10&times; ULN, ALT &gt;3&times; ULN and rising, persistent unexplained muscle pain with CK &gt;5&times; ULN, rhabdomyolysis (dark urine, profound weakness).<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Evidence for Atorvastatin<\/h2>\n<p><strong>CARDS (2004)<\/strong> &mdash; atorvastatin 10 mg in 2,838 type 2 diabetics without overt CVD reduced major CV events by 37% (primary prevention in diabetes). <strong>ASCOT-LLA (2003)<\/strong> &mdash; atorvastatin 10 mg in 10,305 hypertensives reduced CV events by 36%. <strong>TNT (2005)<\/strong> &mdash; 80 mg vs 10 mg in stable CAD; high-dose reduced events by 22%. <strong>PROVE-IT (2004)<\/strong> &mdash; atorvastatin 80 mg vs pravastatin 40 mg post-ACS; atorvastatin superior. <strong>SPARCL (2006)<\/strong> &mdash; atorvastatin 80 mg after stroke\/TIA reduced recurrent stroke by 16%.<\/p>\n<h2 class=\"wp-block-heading\">\u0395\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03b1\u03b9 \u0392\u03b1\u03c3\u03b9\u03c3\u03bc\u03ad\u03bd\u03b5\u03c2 \u03c3\u03b5 \u0391\u03c0\u03bf\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03a7\u03c1\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<ul>\n<li>Primary and secondary prevention of cardiovascular disease in patients with dyslipidaemia<\/li>\n<li>Type 2 diabetes (CARDS) even with &#8220;normal&#8221; LDL<\/li>\n<li>Post-stroke secondary prevention (SPARCL)<\/li>\n<li>Familial hypercholesterolaemia (80 mg; often requires combination with ezetimibe or PCSK9 inhibitor)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Practical Considerations<\/h2>\n<p><strong>Grapefruit juice interacts<\/strong> &mdash; inhibits intestinal CYP3A4, raising atorvastatin levels 2-3 fold. Small amounts (one glass, once) usually OK; regular daily grapefruit should be avoided. <strong>\u0399\u03c3\u03c7\u03c5\u03c1\u03bf\u03af \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2 CYP3A4<\/strong> (clarithromycin, ritonavir, ketoconazole) substantially raise atorvastatin levels and myopathy risk.<\/p>\n<h2 class=\"wp-block-heading\">\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n<p><strong>\u03a3\u03c5\u03c7\u03bd\u03ac (&gt;1%):<\/strong><\/p>\n<ul>\n<li><strong>Myalgia (muscle pain)<\/strong> &mdash; bothersome in 5-10% of users; confirmed statin-associated muscle symptoms with CK rise in 0.1-1%. High nocebo component: SAMSON trial (2020) showed no difference between statin and placebo in double-blind n-of-1 crossovers in many &#8220;statin-intolerant&#8221; patients.<\/li>\n<li><strong>\u0389\u03c0\u03b9\u03b1 \u03b1\u03cd\u03be\u03b7\u03c3\u03b7 \u03c4\u03c1\u03b1\u03bd\u03c3\u03b1\u03bc\u03b9\u03bd\u03ac\u03c3\u03b7\u03c2<\/strong> &mdash; 3% have ALT rise below 3&times; ULN; usually transient and does not require dose change.<\/li>\n<li><strong>New-onset diabetes<\/strong> &mdash; absolute excess ~0.2 per 100 patient-years, mostly in prediabetic patients. CV benefit far exceeds diabetes risk.<\/li>\n<li><strong>Headache, dyspepsia, nausea<\/strong><\/li>\n<li><strong>\u0391\u03bd\u03b9\u03ba\u03b1\u03bd\u03cc\u03c4\u03b7\u03c4\u03b1 \u03c3\u03c4\u03cd\u03c3\u03b7\u03c2<\/strong> (uncommon; mechanism unclear)<\/li>\n<li><strong>Sleep disturbance, cognitive fog<\/strong> (reported but not consistent in RCTs)<\/li>\n<\/ul>\n<p><strong>\u03a3\u03c0\u03ac\u03bd\u03b9\u03b1 \u03b1\u03bb\u03bb\u03ac \u03ba\u03bb\u03b9\u03bd\u03b9\u03ba\u03ac \u03c3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ac:<\/strong><\/p>\n<ul>\n<li><strong>\u03a1\u03b1\u03b2\u03b4\u03bf\u03bc\u03c5\u03cc\u03bb\u03c5\u03c3\u03b7<\/strong> (&lt;1 per 10,000 patient-years) &mdash; severe muscle breakdown, renal failure risk. Stop immediately on dark urine + profound weakness + CK &gt;10&times; ULN.<\/li>\n<li><strong>\u0391\u03bd\u03bf\u03c3\u03bf\u03bc\u03b5\u03c3\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03b7 \u03bd\u03b5\u03ba\u03c1\u03c9\u03c4\u03b9\u03ba\u03ae \u03bc\u03c5\u03bf\u03c0\u03ac\u03b8\u03b5\u03b9\u03b1<\/strong> &mdash; rare persistent myopathy that continues after stopping statin; anti-HMGCR antibody mediated. Needs immunosuppressive treatment.<\/li>\n<li><strong>Severe transaminitis \/ drug-induced liver injury<\/strong> &mdash; rare; stop if ALT &gt;3&times; ULN with symptoms or rising trajectory.<\/li>\n<li><strong>\u03a0\u03b5\u03c1\u03b9\u03c6\u03b5\u03c1\u03b9\u03ba\u03ae \u03bd\u03b5\u03c5\u03c1\u03bf\u03c0\u03ac\u03b8\u03b5\u03b9\u03b1<\/strong> (rare)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/h2>\n<ul>\n<li><strong>\u0395\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7 \u03ba\u03b1\u03b9 \u03b8\u03b7\u03bb\u03b1\u03c3\u03bc\u03cc\u03c2<\/strong> &mdash; statins are contraindicated; cholesterol is required for fetal neurodevelopment.<\/li>\n<li><strong>Active liver disease<\/strong> or unexplained persistent ALT &gt;3&times; ULN.<\/li>\n<li><strong>Prior rhabdomyolysis or severe statin-intolerance<\/strong> confirmed in double-blind rechallenge.<\/li>\n<li><strong>Concurrent strong CYP3A4 inhibitors<\/strong> (for atorvastatin): clarithromycin, itraconazole, ritonavir &mdash; hold statin or switch to rosuvastatin\/pravastatin.<\/li>\n<li>Hypersensitivity to the statin.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n<ul>\n<li><strong>Strong CYP3A4 inhibitors &mdash; CRITICAL.<\/strong> Clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir, cobicistat, ciclosporin &mdash; raise atorvastatin levels 2-10 fold. Hold statin during short antibiotic courses; switch to rosuvastatin or pravastatin for long-term CYP3A4 inhibitor co-therapy.<\/li>\n<li><strong>\u03a7\u03c5\u03bc\u03cc\u03c2 \u03b3\u03ba\u03c1\u03ad\u03b9\u03c0\u03c6\u03c1\u03bf\u03c5\u03c4<\/strong> &mdash; avoid regular daily consumption with atorvastatin (2-3 fold interaction).<\/li>\n<li><strong>Fibrates (gemfibrozil, fenofibrate)<\/strong> &mdash; additive myopathy risk. Gemfibrozil is the worst; fenofibrate is the preferred fibrate for combination. Reserve combinations for specialist dyslipidaemia care.<\/li>\n<li><strong>Niacin high-dose<\/strong> &mdash; additive myopathy risk. Low-dose niacin (1-2 g) usually tolerated.<\/li>\n<li><strong>\u0392\u03b1\u03c1\u03c6\u03b1\u03c1\u03af\u03bd\u03b7<\/strong> &mdash; small INR rise with statin initiation; check INR 1 week after starting. Not a contraindication.<\/li>\n<li><strong>\u039d\u03c4\u03b9\u03b3\u03ba\u03bf\u03be\u03af\u03bd\u03b7<\/strong> &mdash; small digoxin level rise with atorvastatin (P-glycoprotein); usually not clinically significant.<\/li>\n<li><strong>\u0391\u03bb\u03ba\u03bf\u03cc\u03bb<\/strong> &mdash; heavy intake raises liver injury risk. Moderate intake is acceptable.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7<\/h2>\n<p>Store Atorvatin below 25&deg;C in the original blister pack. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3 class=\"wp-block-heading\">Do I have to take Atorvatin at night?<\/h3>\n<p>No &mdash; atorvastatin has a 20-30-hour half-life, long enough that the ~24-hour cycle of nocturnal cholesterol synthesis is covered regardless of dose timing. Morning dosing with other medications is fine. The &#8220;take statins at night&#8221; rule comes from short-half-life statins (simvastatin, lovastatin).<\/p>\n<h3 class=\"wp-block-heading\">What if I get muscle aches on Atorvatin?<\/h3>\n<p>Common and rarely dangerous. Check creatine kinase (CK). If CK is normal, the pains are usually not statin-related &mdash; the SAMSON trial (2020) showed most &#8220;statin-intolerant&#8221; patients had equal aches on placebo in double-blind crossover. Options: continue statin with vitamin D supplementation (if deficient), try coenzyme Q10 (weak evidence but low-risk), switch statin (rosuvastatin has lower muscle-symptom rate than simvastatin and atorvastatin in some trials), lower the dose, or adopt alternate-day dosing. Only stop if CK &gt;10&times; ULN, symptoms are disabling, or there is objective weakness.<\/p>\n<h3 class=\"wp-block-heading\">Will Atorvatin give me diabetes?<\/h3>\n<p>Statins cause a small excess of new-onset diabetes &mdash; approximately 1 extra diabetes case per 1,000 people per year, mostly in those already at high diabetes risk (overweight, prediabetes, family history). The same treatment prevents roughly 5-10 cardiovascular events per 1,000 people per year in the same populations &mdash; so the net benefit is strongly positive. Do not stop a statin because of diabetes risk alone.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Atorvatin with grapefruit juice?<\/h3>\n<p>Occasional small amounts of grapefruit juice (one glass) are usually fine. Daily consumption substantially raises atorvastatin levels (2-3 fold via intestinal CYP3A4 inhibition) and increases myopathy risk. If you drink grapefruit juice regularly, switch to rosuvastatin or pravastatin, which have minimal grapefruit interaction.<\/p>\n<h3 class=\"wp-block-heading\">How long will I need to take Atorvatin?<\/h3>\n<p>Indefinitely, in almost all cases. Stopping a statin causes LDL-C to rebound within weeks and cardiovascular protection is lost within months. Statins are lifelong preventive therapy for atherosclerotic disease, not a short course.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Atorvatin in pregnancy?<\/h3>\n<p>No &mdash; statins are contraindicated in pregnancy and breastfeeding. Cholesterol is required for fetal neurodevelopment; statins cross the placenta. Stop the statin before planned pregnancy; if pregnancy is unplanned, stop immediately and discuss risks with a specialist. Familial hypercholesterolaemia patients can usually safely defer statin therapy during pregnancy and breastfeeding.<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Atorvatin online?<\/h3>\n<p>You can buy Atorvatin (atorvastatin 5 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<h2 class=\"wp-block-heading\">\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ac \u039a\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ac &amp; \u03a5\u03c0\u03b5\u03c1\u03c4\u03b1\u03c3\u03b9\u03ba\u03ac \u03a6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/aldactone\/\">Aldactone &mdash; Spironolactone (non-selective MR antagonist)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/amlode\/\">Amlode &mdash; Amlodipine (CCB)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/lanoxin\/\">Lanoxin &mdash; Digoxin 0.25 mg (cardiac glycoside)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/lotensyl\/\">Lotensyl \u2014 \u039a\u03b9\u03bb\u03bd\u03b9\u03b4\u03b9\u03c0\u03af\u03bd\u03b7 10\/20 mg (L+N-type CCB)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/tenoric\/\">Tenoric &mdash; Atenolol + Chlorthalidone combo<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/zivast-am\/\">Zivast AM &mdash; Atorvastatin + Amlodipine combo<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/high-blood-pressure-medication\/\"><strong>\u03a0\u03b5\u03c1\u03b9\u03ae\u03b3\u03b7\u03c3\u03b7 \u03c3\u03b5 \u03cc\u03bb\u03b1 \u03c4\u03b1 \u03a6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1 \u03b3\u03b9\u03b1 \u03a5\u03c8\u03b7\u03bb\u03ae \u03a0\u03af\u03b5\u03c3\u03b7 \u0391\u03af\u03bc\u03b1\u03c4\u03bf\u03c2<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 \u0399\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u0391\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u0395\u03c5\u03b8\u03cd\u03bd\u03b7\u03c2.<\/strong> \u0391\u03c5\u03c4\u03ae \u03b7 \u03c3\u03b5\u03bb\u03af\u03b4\u03b1 \u03b5\u03af\u03bd\u03b1\u03b9 \u03bc\u03cc\u03bd\u03bf \u03b3\u03b9\u03b1 \u03b5\u03bd\u03b7\u03bc\u03b5\u03c1\u03c9\u03c4\u03b9\u03ba\u03bf\u03cd\u03c2 \u03c3\u03ba\u03bf\u03c0\u03bf\u03cd\u03c2 \u03ba\u03b1\u03b9 \u03b4\u03b5\u03bd \u03b1\u03bd\u03c4\u03b9\u03ba\u03b1\u03b8\u03b9\u03c3\u03c4\u03ac \u03c4\u03b7\u03bd \u03b9\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u03c3\u03c5\u03bc\u03b2\u03bf\u03c5\u03bb\u03ae \u03b1\u03c0\u03cc \u03ad\u03bd\u03b1\u03bd \u03ba\u03b1\u03c4\u03b1\u03be\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b1\u03b3\u03b3\u03b5\u03bb\u03bc\u03b1\u03c4\u03af\u03b1 \u03c5\u03b3\u03b5\u03af\u03b1\u03c2. \u0397 \u03c5\u03c0\u03ad\u03c1\u03c4\u03b1\u03c3\u03b7, \u03b7 \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae \u03b1\u03bd\u03b5\u03c0\u03ac\u03c1\u03ba\u03b5\u03b9\u03b1 \u03ba\u03b1\u03b9 \u03bf\u03b9 \u03b1\u03c1\u03c1\u03c5\u03b8\u03bc\u03af\u03b5\u03c2 \u03b1\u03c0\u03b1\u03b9\u03c4\u03bf\u03cd\u03bd \u03b4\u03b9\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7, \u03c0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7 \u03ba\u03b1\u03b9 \u03b1\u03c4\u03bf\u03bc\u03b9\u03ba\u03ae \u03c0\u03c1\u03bf\u03c3\u03b1\u03c1\u03bc\u03bf\u03b3\u03ae \u03b4\u03cc\u03c3\u03b7\u03c2 \u03b1\u03c0\u03cc \u03b3\u03b9\u03b1\u03c4\u03c1\u03cc \u2014 \u03c0\u03ac\u03bd\u03c4\u03b1 \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03b5\u03af\u03c4\u03b5 \u03b2-\u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2 \u03c5\u03c0\u03cc \u03b9\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u03b5\u03c0\u03af\u03b2\u03bb\u03b5\u03c8\u03b7.<\/div>\n<h3 class=\"wp-block-heading\">\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>Atorvatin is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our <a href=\"\/el\/medsbase-re-shipment-assurance-policy\/\">\u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a>. \u039f \u03c4\u03af\u03c4\u03bb\u03bf\u03c2 \u03c7\u03c1\u03ad\u03c9\u03c3\u03b7\u03c2 \u03c3\u03c4\u03b7\u03bd \u03ba\u03ac\u03c1\u03c4\u03b1 \u03c3\u03b1\u03c2 \u03b5\u03bc\u03c6\u03b1\u03bd\u03af\u03b6\u03b5\u03b9 \u03c4\u03bf\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03b6\u03cc\u03bc\u03b5\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd (\u03ad\u03bd\u03b1\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03b6\u03cc\u03bc\u03b5\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1), \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2<\/h3>\n<p>\u0386\u03bb\u03bb\u03b1 \u03c0\u03c1\u03bf\u03ca\u03cc\u03bd\u03c4\u03b1 \u03c3\u03b5 <strong>\u03a7\u03c1\u03cc\u03bd\u03b9\u03b5\u03c2 \u03a0\u03b1\u03b8\u03ae\u03c3\u03b5\u03b9\u03c2<\/strong> \u03c0\u03bf\u03c5 \u03bf\u03b9 \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 \u03b5\u03be\u03b5\u03c4\u03ac\u03b6\u03bf\u03c5\u03bd \u03b5\u03c0\u03af\u03c3\u03b7\u03c2:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/glycomet-sr\/\">Glycomet SR<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/tegrital\/\">Tegrital 100 mg Chewable (Carbamazepine) \u2014 Trigeminal Neuralgia &amp; Seizures<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/ramisave\/\">Ramisave<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/diamox\/\">Diamox<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/laregab-at\/\">Laregab AT (Gabapentin 300 mg + Amitriptyline 10 mg) \u2014 Refractory Nerve Pain<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Atorvatin is atorvastatin 5 mg tablets \u2014 useful sub-therapeutic starting dose for patients requiring gentle titration (frail elderly, CYP3A4 interaction-prone, history of myalgia on higher statin doses). Standard atorvastatin monotherapy starts at 10-20 mg; 5 mg is a stepping-stone for tolerability-limited initiation. LDL reduction roughly 30-35% vs placebo at 5 mg. Full indication profile of atorvastatin \u2014 CV primary and secondary prevention.<\/p>","protected":false},"featured_media":61589,"comment_status":"closed","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356,3953],"product_tag":[3435,5065],"class_list":{"0":"post-61588","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_cat-high-cholesterol-treatments","11":"product_tag-atorvastatin","12":"product_tag-atorvatin","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/61588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=61588"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/61589"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=61588"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=61588"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=61588"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=61588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}